CMMB

Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, headquartered in Tel Aviv, Israel. The company's lead product candidate is nebokitug (CM-101), a monoclonal antibody that neutralizes CCL24 activity, currently in development for primary sclerosing cholangitis (PSC) and systemic sclerosis. Chemomab has reported positive results from the Phase 2 SPRING trial in PSC patients, achieving the primary safety endpoint and showing improvements across a wide range of disease-related secondary endpoints at both 15-week and 48-week timepoints. The company is preparing for Phase 3 trials while pursuing strategic partnerships to optimize development resources, with its CM-101 program for systemic sclerosis Phase 2-ready and an open U.S. IND.